Omeros (NASDAQ:OMER) Trading Up 6.4% - Still a Buy?

Omeros Co. (NASDAQ:OMER - Get Free Report) shares shot up 6.4% during trading on Thursday . The stock traded as high as $8.96 and last traded at $9.07. 309,440 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 530,454 shares. The stock had previously closed at $8.52.

Analysts Set New Price Targets

OMER has been the subject of a number of research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Omeros in a report on Friday, March 21st. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Friday, January 17th. Finally, StockNews.com downgraded Omeros from a "hold" rating to a "sell" rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Stock Down 3.0 %

The firm has a market capitalization of $476.35 million, a price-to-earnings ratio of -3.56 and a beta of 2.03. The company has a 50-day moving average price of $8.69 and a 200-day moving average price of $7.55.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Truvestments Capital LLC increased its stake in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros during the fourth quarter valued at approximately $46,000. BNP Paribas Financial Markets raised its holdings in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management lifted its position in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 4,404 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.